Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy
نویسندگان
چکیده
منابع مشابه
Cancer Therapy: Preclinical Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth
Purpose: Angiogenesis is a key process in tumor progression. By binding VEGF, VEGF receptor-2 (VEGFR2) is a main signaling transducer in tumor-associated angiogenesis. Accordingly, therapeutic approaches against the VEGF/VEGFR2 signaling axis have been designed. However, an efficient and specific chemotherapeutic targeting of tumor-associated endothelial cells has not yet been achieved. Experim...
متن کاملPreclinical evaluation of TriMix and antigen mRNA-based anti-tumor therapy mRNA-based anti-tumor vaccination
This work was supported by grants from the Interuniversity Attraction Poles Program-Belgian State-Belgian Science Policy, the National Cancer Plan of the Federal Ministry of Health, the Stichting tegen Kanker, the Vlaamse Kanker Liga, an Integrated Project and an EU FP6funded Network of Excellence, an IWT-TBM program, the FWO-Vlaanderen and the Scientific Fund Willy Gepts of the University hosp...
متن کاملTargeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.
PURPOSE Angiogenesis is a key process in tumor progression. By binding VEGF, VEGF receptor-2 (VEGFR2) is a main signaling transducer in tumor-associated angiogenesis. Accordingly, therapeutic approaches against the VEGF/VEGFR2 signaling axis have been designed. However, an efficient and specific chemotherapeutic targeting of tumor-associated endothelial cells has not yet been achieved. EXPERI...
متن کاملCancer Therapy: Preclinical Carbonic Anhydrase IX Promotes Tumor Growth and Necrosis In Vivo and Inhibition Enhances Anti-VEGF Therapy
Purpose: Bevacizumab, an anti-VEGFA antibody, inhibits the developing vasculature of tumors, but resistance is common. Antiangiogenic therapy induces hypoxia and we observed increased expression of hypoxia-regulated genes, including carbonic anhydrase IX (CAIX), in response to bevacizumab treatment in xenografts. CAIX expression correlates with poor prognosis inmost tumor types andwith worse ou...
متن کاملAnti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
Background OX40, a TNFRSF member, is a co-stimulatory molecule expressed on antigen experienced effector T (Teff) and regulatory T (Treg) cells, including infiltrating cells in mouse and human tumors. Activation of OX40 by agonistic antibodies is hypothesized to promote anti-tumor immunity by enhancing Teff activation and inhibiting Treg mediated suppression. We conducted in vitro and in vivo p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncotarget
سال: 2019
ISSN: 1949-2553
DOI: 10.18632/oncotarget.27148